USO DE ANÁLOGOS DE GLP-1 COMO FATOR PROTETOR CARDIOVASCULAR E RENAL

View at publisher Summarise with VIRAT
Authors: Giovana Pereira Lopes, Camila Godoy Sabatini, Mirela Moreira Godoy Sabatini
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists have become established as fundamental therapies in the management of type 2 diabetes mellitus and obesity, initially recognized for their effects on glycemic control and weight reduction. Robust evidence from randomized clinical trials and outcome studies has expanded this understanding, demonstrating that these agents confer clinically significant cardiovascular and renal benefits, independent of glycemic control alone. This chapter aimed to analyze the role of GLP-1 analogs as cardiovascular and renal protective factors in light of contemporary scientific evidence. This is a systematic review of the literature conducted using the PubMed database, including studies published over the past five years. The findings indicate a consistent reduction in major cardiovascular events, such as acute myocardial infarction and stroke, as well as a decrease in the progression of chronic kidney disease, with preservation of glomerular filtration rate and reduction in adverse renal outcomes. Recent trials have also demonstrated cardiovascular benefits in individuals with obesity and established cardiovascular disease, even in the absence of diabetes. It is concluded that GLP-1 analogs represent a therapeutic strategy with significant impact on reducing cardiovascular and renal morbidity and mortality, and should be considered central components in the integrated management of patients at high cardiometabolic risk.

Fields of Study & Subjects

Diabetes Treatment and Management Chronic Kidney Disease and Diabetes Pharmacology and Obesity Treatment

Publication details

Pages
303–309
Publication date
24 March 2026
Language
EN
Document type
Book chapter